The Weekly Roundup: December 10-15

Upadacitinib for Vitiligo Improves Patient Health-Related QoL After 24 Weeks

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference.

Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Vitiligo Case Report: Rapid Onset of White Patches on Face, Neck, and Arms

Raj Chovatiya, MD, PhD, reviews a case of an adolescent patient with rapid changes in existing vitiligo.

Study Finds Association Between Vitiligo and Osteoporosis

A poster presented at the 2023 ReV Virtual Conference explored the association between the 2 conditions.

Association Found Between Atopic Dermatitis and Altered Oral Microbiome

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

Patient Perspective: I Am More Than My Atopic Dermatitis

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Expert Insights on AAD’s Updated AD Management Guidelines for Using Phototherapy and Systemic Therapies

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

5-Year Safety Data Leaves Investigators Optimistic in Upadacitinib for AD Management

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Journal Digest: December 12

This week’s collection of the latest dermatologic studies covers skin cancer risk associated with phototherapy excluding psoralens, the role of the mycobiome in the development of atopic diseases, underrecognized pediatric vulvar diseases, and sunscreen deserts in Northeast, Ohio.

Adalimumab (Humira) Biosimilar Well-Received By Patients Following US Launch

In January 2023, adalimumab-atto became the first biosimilar product available for the reference product adalimumab.

Dupilumab Treatment Improved Epidermal Neuroanatomy in Patients With Atopic Dermatitis

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

What's New in Aesthetics With Heidi Prather, MD

Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.

Raj Chovatiya, MD, PhD: Advancements in Topical Therapies for Atopic Dermatitis

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

Seasonal Efficacy and Tolerability of Tazarotene in Warmer vs Colder Months

Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.

Almirall and Etherna Collaborate to Develop mRNA-Based Therapies for Severe Skin Diseases

One of the specific areas of focus will be non-melanoma skin cancer.

Phase 1/2 Trial of AIV001 (Axitinib) for Basal Cell Carcinoma Concludes With Promising Data

The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.

Multi-Omics Psoriasis Treatment Approach

Study authors hypothesize that a monoclonal blockade of pathogenic T cells may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis.

Dermoscopic Monitoring of Vitiligo Lesions Reveal Disease Activity, Evolution Insights

Lesional stability is a necessary requirement for determining the course of treatment for vitiligo.

Psoriasis Treatment Center of New Jersey Reports Positive Results for Tapinarof in Psoriasis Trial

52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.

Skin Care Terms to Keep on Your Radar

Staying on top of products and ingredients patients are asking about is critical, especially this holiday season as they are considering gifts for loved ones.

Teva and Biolojic Design Announce Exclusive License Agreement to Develop Antibody for AD and Asthma

Biolojic’s BD9 is a dual-specific antibody that can block both Thymic stromal lymphopoietin and IL-13.

All Things JAKs for Vitiligo

David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.

New Treatments Bring Hope for Autoimmune Skin Conditions

The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.

Recapping the 2023 RAD and ReV Virtual Conferences

Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.